<a href="https://www.fiercebiotech.com/biotech/ascendis-axes-il-2-program-retreat-oncology-expansion" hreflang="en">Ascendis axes IL-2 program in retreat from oncology expansion </a>
Ascendis Pharma has discontinued its internal development of the IL-2 candidate, onvapegleukin alfa, to refocus on its core business in rare endocrinology diseases, despite previously pursuing opportunities in oncology. The decision follows a strategic realignment as the company seeks to maximize the value of its remaining assets.
Ascendis Pharma's decision to halt its internal IL-2 oncology program underscores the critical importance of aligning R&D efforts with strategic focus, particularly for companies with established expertise in niche areas like rare endocrinology diseases. For professionals tracking biotech trends, this move highlights the challenges and risks associated with branching into complex fields such as oncology, where overcoming existing hurdles like cytokine toxicity is still a significant barrier despite historical efforts and large investments. Consider the strategic implications for startups in healthtech and biotech aiming to expand beyond their core competencies.